Hsbc Holdings PLC Has $347.44 Million Position in Bristol Myers Squibb Company $BMY

Hsbc Holdings PLC grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 32.6% during the 4th quarter, HoldingsChannel reports. The fund owned 6,424,715 shares of the biopharmaceutical company’s stock after acquiring an additional 1,578,830 shares during the period. Hsbc Holdings PLC’s holdings in Bristol Myers Squibb were worth $347,435,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of BMY. Swiss RE Ltd. purchased a new position in Bristol Myers Squibb in the fourth quarter valued at about $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the 2nd quarter worth about $25,000. Physician Wealth Advisors Inc. raised its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Bayban acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 0.2%

Shares of BMY stock opened at $54.10 on Friday. The stock’s 50 day simple moving average is $57.34 and its 200 day simple moving average is $57.09. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a market capitalization of $110.48 billion, a price-to-earnings ratio of 15.20, a PEG ratio of 0.15 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the business earned $1.80 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.7%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Insider Activity

In related news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. HSBC boosted their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Guggenheim restated a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Bank of America cut their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.